A high proportion of ITP patients were found to be without any of the treatments assessed in this study, partially because of under-recording of treatment administered by specialists or in hospitals. Further studies are warranted to validate the needs for treatment for the untreated ITP patients by evaluating the level of platelet count at and post ITP diagnosis. In addition, because the study evaluates rare events in patients with a rare condition, the number of cases is small and the precision of incidence estimations is relatively selleck kinase inhibitor
low, especially when the analysis is stratified by treatment types. ITP is a rare but serious medical condition that has not been adequately studied, especially with regard to clinical course, progression, and concurrent or secondary disorders. Using a large EMR database, this study is the first that investigated the risk factors and incidence of RI, HU, and HE related to ITP diagnosis and various ITP treatments. The results did not suggest significant difference of the risks in ITP patients with or without specific treatment relative to those in the non-ITP population. The sample size of this study restricts evaluation of IVIG treatment and treatment changes over time. Chronic ITP in the GPRD cannot be assessed by coding alone. Future studies are warranted to advance the research by further addressing these limitations. ""Platelets are activated in sickle cell disease (SCD), and particularly during vaso-occlusive episodes (VOE). Thrombospondin-1 (TSP1), 3-Methyladenine
a major secretory product of activated platelets, is increased in the circulation www.selleckchem.com
in VOE and binds to sickle red blood cells (RBC) promoting vascular adhesion. Thus, we hypothesized that TSP1 may represent a plasma biomarker of disease severity in SCD. We tested the plasma collected from patients in steady state (n = 27) and VOE (n = 14), as well as healthy controls (n = 17) at the University of Pittsburgh Medical Center (UPMC), and from patients in steady state enrolled in the walk-PHaSST clinical trial (n = 483). We found that TSP1 levels were increased in VOE in the UPMC cohort. Among steady-state patients at UPMC, TSP1 values correlated positively with lifetime history of acute chest syndrome (r = 0.72, P < 0.0001) and hemoglobin concentration (r = 0.49, P = 0.01), and negatively with markers of hemolysis, such as LDH (r = ?0.50, P = 0.009). Analysis of the walk-PHaSST cohort also showed a positive association between TSP1 levels and hydroxyurea use (r = 0.14, P = 0.003), and confirmed the negative associations with the severity of hemolysis. Our results suggest that TSP1 levels are associated with more VOE, hydroxyurea use and lower rates of hemolysis.